Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2002

View Archived Issues

Maxim reports advances in its proapoptotic drug discovery program

Replikins: new targets for the detection and treatment of cancer

Potential antianginal efficacy of the selective, orally active Na+/H+ exchange inhibitor SMP-300

Hollis-Eden collaborating on development of Aeson's lead compound

3-DP licenses GSK TPO mimetic

Natural antibacterial compound acts by inhibiting protein translocation

Microbial metabolite pipalamycin induces apoptosis in cancer cells

RWJ-54428 active against a wide spectrum of resistant Gram-positive cocci

MDA-7 expression lost with progression of melanoma; data support use of INGN-241 in melanoma

Cidecin safe and effective in complicated urinary tract infections

Four compounds targeted for clinical development at ExonHit

Orphan drug status granted for SS1-PE38 in mesothelioma and ovarian cancer

Surfaxin granted orphan drug status in ALI/ARDS

Interneuron highlights recent accomplishments, announces name change

Active Biotech presents annual account for 2001

Aciphex indications expanded

KW-6002 completes phase IIa trials in Parkinson's disease

Yamanouchi gains access to TransGenic knockout mice gene function information

Insmed and Oxagen collaborate on genetic study of PCOS

Takeda takes control of joint venture with Gruenenthal

Compounds with affinity for 5-HT1A receptors described in patent by Knoll

Abbott claims phenylsulfanyl derivatives for inflammation, etc.

Selective inhibitors of COX-2 synthesized at Merck Frosst

Taisho identifies compounds with use in psychiatric and neurological disorders

Pyrrole derivatives with HIV reverse transcriptase-inhibitory activity described in patent

Sugen prepares inhibitors of protein kinases with potential in cancer, etc.

ABI-007 status in breast cancer updated

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...